Author

Carlos Fernandez

Institution: Insmed (United States)

Observed institution: Insmed (United States)

ORCID: 0009-0009-8319-1335

Observed ORCID: 0009-0009-8319-1335

OpenAlex ID: A5125520726

Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study

2026 · Amelia Shoemark, Emma D Johnson, et al. · The Lancet Respiratory Medicine · 4

Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial

2026 · Kozo Morimoto, James D. Chalmers, et al. · Respiratory Investigation · 2

Population Pharmacokinetic Analysis of Brensocatib in Adult and Adolescent Patients With Non‐Cystic Fibrosis Bronchiectasis

2026 · Helen Usansky, Anthony Cammarata, et al. · CPT Pharmacometrics & Systems Pharmacology · 1

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) – The BiRCh Study

2026 · Philippe Gevaert, Randall Ow, et al. · Journal of Allergy and Clinical Immunology

Works count: 4

Citation count: 7

H-index: 2

I10-index: